Tomás José González-López

Dr. Tomás José González-López

Hospital Universitario de Burgos, Burgos, Castille-Leon, Spain
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2014 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
Tomás José González-LópezTomás José González-López
Tomás José González-López
CPCristina Pascual
Cristina Pascual
MÁMaría Teresa Álvarez‐Román
María Teresa Álvarez‐Román
FFFernando Fernández‐Fuertes
Fernando Fernández‐Fuertes
BSBlanca Sánchez‐González
Blanca Sánchez‐González
JGJosé Ramón González‐Porras
José Ramón González‐Porras
Eltrombopag is effective and safe in immune thrombocytopenia (ITP). Some patients may sustain their platelet response when treatment is withdrawn but the frequency of this phenomenon is unknown. We retrospectively evaluated 260 adult primary ITP patients (165 women and 95 men; median age, 62 years) treated with eltrombopag after a median time from diagnosis of 24 months. Among the 201 patients who achieved a complete remission (platelet count >100 × 109/l), eltrombopag was discontinued in 80 patients. Reasons for eltrombopag discontinuation were: persistent response despite a reduction in dose over time (n = 33), platelet count >400 × 109/l (n = 29), patient's request (n = 5), elevated aspartate aminotransferase (n = 3), diarrhea (n = 3), thrombosis (n = 3), and other reasons (n = 4). Of the 49 evaluable patients, 26 patients showed sustained response after discontinuing eltrombopag without additional ITP therapy, with a median follow‐up of 9 (range, 6–25) months. These patients were characterized by a median time since ITP diagnosis of 46.5 months, with 4/26 having ITP < 1 year. Eleven patients were male and their median age was 59 years. They received a median of 4 previous treatment lines and 42% were splenectomized. No predictive factors of sustained response after eltrombopag withdrawal were identified. Platelet response following eltrombopag cessation may be sustained in an important percentage of adult primary ITP patients who achieved CR with eltrombopag. However, reliable markers for predicting which patients will have this response are needed. Am. J. Hematol. 90:E40–E43, 2015.

10 March 2022 in Blood
Verified
Journal Article
Open access
PDF file
Livio PaganoLivio Pagano
Livio Pagano
JSJon Salmanton-García
Jon Salmanton-García
FMFrancesco Marchesi
Francesco Marchesi
Alberto Lopez GarciaAlberto Lopez Garcia
Alberto Lopez Garcia
SLSylvain Lamure
Sylvain Lamure
OCOliver A. Cornely
Oliver A. Cornely
In a Plenary Paper, Mittelman and colleagues assess the relative clinical efficacy of mRNA vaccination on COVID-19 disease incidence and outcomes in patients with hematologic malignancies compared with healthy matched controls. This population-based study from Israel links prior observations of poor serologic responses to vaccination to higher risk for breakthrough infection, hospitalization, and death in patients with blood cancer, especially those on active antineoplastic therapy. In an accompanying Letter to Blood, Pagano et al provide supportive data using a multination survey approach to capture outcomes for COVID-19 in vaccinated patients with hematologic neoplasms. They also emphasize the higher risk among patients with lymphoid malignancies. Together, these findings argue for both continued deployment of booster programs and ongoing public health guidance for this vulnerable group.

18 December 2014 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
JGJosé Ramón González‐Porras
José Ramón González‐Porras
MMMaría Eva Mingot-Castellano
María Eva Mingot-Castellano
MAMarcio M. Andrade
Marcio M. Andrade
RARafael Alonso
Rafael Alonso
ICIsabel Caparrós
Isabel Caparrós
Tomás José González-LópezTomás José González-López
Tomás José González-López

30 June 2017 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
Tomás José González-LópezTomás José González-López
Tomás José González-López
FFFernando Fernández-Fuertes
Fernando Fernández-Fuertes
JHJosé-Ángel Hernández-Rivas
José-Ángel Hernández-Rivas
BSBlanca Sánchez-González
Blanca Sánchez-González
VMVioleta Martínez-Robles
Violeta Martínez-Robles
JGJosé Ramón González-Porras
José Ramón González-Porras

8 August 2024 in Blood
Verified
Journal Article
Closed access
PDF file
Tomás José González-LópezTomás José González-López
Tomás José González-López
NBNuria Bermejo-Vega
Nuria Bermejo-Vega
RCRocío Cardesa-Cabrera
Rocío Cardesa-Cabrera
VMVioleta Martínez-Robles
Violeta Martínez-Robles
GAGerardo Aguilar-Monserrate
Gerardo Aguilar-Monserrate
GGGloria García-Donas Gabaldón
Gloria García-Donas Gabaldón
Fostamatinib, a recently approved Syk inhibitor used in adult primary immune thrombocytopenia (ITP), has been shown to be safe and effective in this disorder. However, clinical trial results may not be similarly reproduced in clinical practice. Here, 138 patients with ITP (both primary and secondary) from 42 Spanish centers who had been treated with fostamatinib were evaluated prospectively and retrospectively. The median age of our cohort (55.8% women) was 66 years (interquartile range [IQR], 56-80). The median time since ITP diagnosis at fostamatinib initiation was 51 months (IQR, 10-166). The median number of therapies before fostamatinib initiation was 4 (IQR, 2-5), including eltrombopag (76.1%), romiplostim (57.2%), and IV immunoglobulins (44.2%). Fifty-eight patients (42.0%) had signs/symptoms of bleeding in the month before treatment initiation. Seventy-nine percent of patients responded to fostamatinib with 53.6% complete responses (platelet count > 100 × 109/L). Eighty-three patients (60.1%) received fostamatinib monotherapy, achieving a high response rate (85.4%). The proportion of time in response during the 27-month period examined was 83.3%. The median time to platelet response was 11 days (IQR, 7-21). Sixty-seven patients (48.5%) experienced adverse events, mainly grade 1 to 2; the commonest of which were diarrhea (n = 28) and hypertension (n = 21). One patient had deep venous thrombosis, and one patient developed acute myocardial infarction. Fostamatinib was shown to be effective with good safety profile in patients with primary and secondary ITP across a wide age spectrum in this real-world study.

29 June 2023 in Blood Reviews
Verified
Journal Article
Closed access
Tomás José González-LópezTomás José González-López
Tomás José González-López
DPDrew Provan
Drew Provan
ABAbelardo Bárez
Abelardo Bárez
ABAngel Bernardo-Gutiérrez
Angel Bernardo-Gutiérrez
SBSilvia Bernat
Silvia Bernat
FFFernando Fernández-Fuertes
Fernando Fernández-Fuertes